Stay updated with breaking news from Genomics Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eagle Asset Management Inc. trimmed its position in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 729,476 shares of the company’s stock after selling 5,710 shares during the period. Eagle […]
Pier 88 Investment Partners LLC cut its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 51.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,690 shares of the company’s stock after selling 5,000 shares during the period. Pier 88 […]
10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 4,877 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $118,511.10. Following the transaction, the chief executive officer now owns 889,641 shares of the company’s […]
10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 4,877 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the sale, the chief executive officer now directly […]
10x Genomics (NASDAQ:TXG – Free Report) had its target price lowered by Canaccord Genuity Group from $65.00 to $50.00 in a report released on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. Several other equities analysts have also recently commented on TXG. Deutsche Bank Aktiengesellschaft decreased their price target […]